anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) refers to ALL patients with t(9;22) cytogenetic abnormalities, accounting for about 25% of ALL. Lung adenocarcinoma (LUAD) is the most common pathological type of non-small-cell lung cancer, which has a frequency of approximately 45% cases with mutations in EGFR. Both Ph+ ALL and EGFR mutant LUAD are involved in the pathogenesis of the abnormal activation of the tyrosine kinase pathway. Although the second primary hematological malignancy after the treatment of solid tumors is common in clinics, the synchronous multiple primary malignant tumors of hematological malignancy overlap solid tumors are uncommon, even both tumors involved in the pathogenesis of the abnormal activation of the tyrosine kinase pathway are extremely rare.
CASE PRESENTATION: An 84-year-old man with fatigue and dizziness was diagnosed with Ph+ ALL. Meanwhile, a chest CT indicated a space-occupying lesions, characterized by the presence of void, in the right lower lope with the enlargement of mediastinal lymph node and right pleural effusion. After a few weeks, the patient was diagnosed with LUAD with EGFR exon 19 mutation. Both tyrosine kinase inhibitors (TKI) (Flumatinib) and EGFR-TKI (Oxertinib) was used for the patients, and finally have controlled both diseases.
CONCLUSION: As far as we know, we for the first time reported a case of Ph+ ALL and EGFR mutant LUAD synchronous overlap, of which pathogenesis is related to abnormal tyrosine kinase activation. This patient was successfully treated with two different TKIs without serious adverse events.
Cancer cachexia (CC) is a multifactorial and complex syndrome experienced by up to 80% of patients with cancer and implicated in ∼40% of cancer-related deaths. Given its significant impact on patients' quality of life and prognosis, there has been a growing emphasis on elucidating the underlying mechanisms of CC using preclinical models. However, the mechanisms of cachexia appear to differ across several variables including tumor type and model and biologic variables such as sex. These differences may be exacerbated by variance in experimental approaches and data reporting. This review examines literature spanning from 2011 to March 2024, focusing on common preclinical models of CC, including Lewis Lung Carcinoma, pancreatic KPC, and colorectal colon-26 and Apcmin/+ models. Our analysis reveals considerable heterogeneity in phenotypic outcomes, and investigated mechanisms within each model, with particular attention to sex differences that may be exacerbated through methodological differences. Although searching for unified mechanisms is critical, we posit that effective treatment approaches are likely to leverage the heterogeneity presented by the tumor and pertinent biological variables to direct specific interventions. In exploring this heterogeneity, it becomes critical to consider methodological and data reporting approaches to best inform further research.
Chronic obstructive pulmonary disease (COPD) and asthma are the most common chronic respiratory diseases. In middle-aged and elderly patients, it is difficult to distinguish between COPD and asthma based on clinical symptoms and pulmonary function examinations in clinical practice. Thus, an accurate and reliable inspection method is required. In this study, we aimed to identify breath biomarkers and evaluate the accuracy of breathomics-based methods for discriminating between COPD and asthma. In this multi-center cross-sectional study, exhaled breath samples were collected from 89 patients with COPD and 73 with asthma and detected on a high-pressure photon ionization time-of-flight mass spectrometry (HPPI-TOFMS) platform from 20 October 2022, to 20 May 2023, in four hospitals. Data analysis was performed from 15 June 2023 to 16 August 2023. The sensitivity, specificity, and accuracy were calculated to assess the overall performance of the volatile organic component (VOC)-based COPD and asthma discrimination models. Potential VOC markers related to COPD and asthma were also analyzed. The age of all participants ranged from to 18-86 years, and 54 (33.3%) were men. The age [median (minimum, maximum)] of COPD and asthma participants were 66.0 (46.0, 86.0), and 44.0 (17.0, 80.0). The male and female ratio of COPD and asthma participants were 14/75 and 40/33, respectively. Based on breathomics feature selection, ten VOCs were identified as COPD and asthma discrimination biomarkers via breath testing. The joint panel of these ten VOCs achieved an area under the curve of 0.843, sensitivity of 75.9%, specificity of 87.5%, and accuracy of 80.0% in COPD and asthma discrimination. Furthermore, the VOCs detected in the breath samples were closely related to the clinical characteristics of COPD and asthma. The VOC-based COPD and asthma discrimination model showed good accuracy, providing a new strategy for clinical diagnosis. Breathomics-based methods may play an important role in the diagnosis of COPD and asthma.
The invention provides a method for recommending a diet structure for a diabetic based on an artificial intelligence technology. This technology requires collecting and processing a large number of hospitals and reliable data on the network to build a database, and storing the database in the cloud. When a user is recommended to diet, the data of the user needs to be acquired from each terminal by relying on the technology of the internet of things. After the data is acquired, the acquired data is sorted and converted by means of an artificial intelligence model. According to the data of arrangement and conversion, similar cases are found out from the database, and machine learning and deep learning models are built by using the cases. And obtaining optimal diet recommendation according to the model and the optimization theory, and feeding back to the user through the terminal.
Myotonic dystrophy type 1 (DM1) is a hereditary disease characterized by muscular impairments. Fundamental and clinical positive effects of strength training have been reported in men with DM1, but its impact on women remains unknown. We evaluated the effects of a 12-week supervised strength training on physical and neuropsychiatric health. Women with DM1 performed a twice-weekly supervised resistance training program (3 series of 6-8 repetitions of squat, leg press, plantar flexion, knee extension, and hip abduction). Lower limb muscle strength, physical function, apathy, anxiety and depression, fatigue and excessive somnolence, pain, and patient-reported outcomes were assessed before and after the intervention, as well as three and six months after completion of the training program. Muscle biopsies of the vastus lateralis were also taken before and after the training program to assess muscle fiber growth. Eleven participants completed the program (attendance: 98.5 %). Maximal hip and knee extension strength (p < 0.006), all One-Repetition Maximum strength measures (p < 0.001), apathy (p = 0.0005), depression (p = 0.02), pain interference (p = 0.01) and perception of the lower limb function (p = 0.003) were significantly improved by training. Some of these gains were maintained up to six months after the training program. Strength training is a good therapeutic strategy for women with DM1.
Toxic effects accompanying acute overdosage of clomiphene citrate tablets USP have not been reported. Signs and symptoms of overdosage as a result of the use of more than the recommended dose during clomiphene citrate tablets USP therapy include nausea, vomiting, vasomotor flushes, visual blurring, spots or flashes, scotomata, ovarian enlargement with pelvic or abdominal pain. (See CONTRAINDICATIONS: Ovarian Cyst.)

Oral LD50. The acute oral LD50 of clomiphene citrate tablets USP is 1700 mg/kg in mice and 5750 mg/kg in rats. The toxic dose in humans is not known.

Dialysis. It is not known if clomiphene citrate tablets USP is dialyzable.
Graft vs. host disease represents the most formidable problem following allogeneic hematopoietic stem cell transplantation for hematological diseases. Chronic graft-versus-host disease (cGVHD) is the most serious and common long-term complication of this treatment in patients surviving more than 100 days. Some patients are requiring immunosuppressive therapy for years. cGVHD is associated with a high degree of morbidity and mortality and remains a major cause of late death. When standard treatment with steroids is ineffective or poorly tolerated, effective therapeutic options are limited. Patients with uncontrolled cGVHD with initial therapy including systemic steroids respond poorly to second line options. Recent studies have demonstrated Bortezomib safety in the prophylaxis, and improvement of GVHD suggesting its efficacy.This study is done to evaluate the potential of bortezomib in treating refractory cGVHD.
Magnesium sulfate sodium potassium solution group: 3L magnesium sulfate sodium potassium oral concentrated solution. At 18:00 1d before the inspection, dissolve a package of contents into 200ml with water, and drink 250ml of water every half hour after that, drinking a total of 6 cups (that is, 1.5L); On the day of the examination (6 hours before the colonoscopy) repeat the same medication as the previous evening.
NEW MATERIAL:A compound (salt) expressed by formula I (R<1> is alkoxy, acyloxy, acylamino, etc.; R<2> is H, halogen hydroxy, alkoxy, aryloxy, etc,; A is 2-trialkylaminoethyl). EXAMPLE:1-O-Octadecyl-2-acetyl-3-thioglycerol-3-phosphorylcholine. USE:An anti-inflammatory and analgesic agent, antiallergic agent and agent for cardiovascular systems as well as respiratory organs. PREPARATION:For example, epibromohydrin expressed by formula II is reacted with an alcohol to alkylate the 1-position and then converted into a disulfide with NaSH. The hydroxyl group at the 2-position is then acrylated to give a compound expressed by formula III, which is reacted with SO2Cl2 and dimethyl phosphite and successively NaI and ethylene bromohydrin to provide a compound compound formula IV. The resultant compound expressed by formula IV is then reacted with trimethylamine, etc., to afford the aimed compound expressed by formula I.
The study takes place over two sessions over a period of 7 days. The duration of the sessions is approx. 4 hours in total. In the 1st session, a squared area of 4x4 cm will be selected at the center of each middle forearm of the subject. The two areas will be randomly treated with one of the following substances: cowhage, histamine, BAM 8-22 or vehicle. Each substance will be applied for 10 minutes, during which the pain/itch following the substance application will be monitored. Twenty minutes after each application, the measurements with FLPI will be conducted. Then the measurements of alloknesis and mechanically evoked itch, will be conducted. This procedure will be repeated three times for each substance; so in total each substance will be applied three times, each application lasting 10 minutes.
Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events.
Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. The invention relates to a concept for the decoration of a support, in particular of interior surfaces of a building, in which concept a dry composition, intended to be mixed with water, is used to more easily prepare a paste that can be applied to the support, with a view to producing a decorative coating having a ?concrete feel?, a ?concrete appearance?, a ?concrete hardness?, and which can moreover be removed using a wallpaper steam stripper. To achieve this objective, the invention firstly relates to a dry pulverulent composition comprising, in weight percent on a dry basis: from 30 to 60 of cement, from 30 to 60 of filler, from 0.5 to 10 of at least one absorbent, from 0.01 to 1 of at least one fibrous flexibilizing agent, from 0.01 to 3 of at least one retarder, from 0.01 to 1 of wetting agent, from 0.1 to 20 of decorative particles, from 0.5 to 10 of at least one hardener, and from 0 to 1 of at least one colorant. The invention also relates to a method of preparing a paste by mixing this composition with water, and also to a method of obtaining a concrete decorative coating. The invention also relates to the tools used for this method, namely, in particular, a notched float for the application of the paste, a fan rake for creating a scratched effect, a nylon bristle brush for creating a brushed or combed effect, a two-blade structuring spatula for creating a striped or striated effect. The invention finally relates to a decorative coating kit for interior surfaces of a building comprising the aforementioned composition, at least one of the aforementioned tools, (optionally) a smoothing spatula and at least one of the following components or accessories, primer for basecoats, sponge for blending effect, specific colorant, product for white or coloured haze, protective varnish or wax.
Participants will receive velcade 1.3 mg/m\^2 as SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9, melphalan 9 mg/m\^2, orally, once daily (on Days 1-4) and prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9. In addition participants will also receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. On days when daratumumab is given, dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute, and prednisone 60 mg/m2 once daily will be given on Days 2-4. Following amendment 7, participants will have the option to switch to daratumumab subcutaneous (SC) on Day 1 of any cycle, at the discretion of the investigator.
###  General

As management of overdose is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment.   
  
In order to protect against the rare but potentially critical manifestations described above, obtain an ECG and immediately initiate cardiac monitoring. Protect the patient’s airway, establish an intravenous line and initiate gastric decontamination. Observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. Monitoring of plasma drug levels should not guide management of the patient. Dialysis is probably of no value because of low plasma concentrations of the drug.

###  Gastrointestinal Decontamination

All patients suspected of an overdose with cyclobenzaprine hydrochloride should receive gastrointestinal decontamination. This should include large volume gastric lavage followed by activated charcoal. If consciousness is impaired, the airway should be secured prior to lavage and emesis is contraindicated.

###  Cardiovascular

A maximal limb-lead QRS duration of ≥0.10 seconds may be the best indication of the severity of the overdose. Serum alkalinization, to a pH of 7.45 to 7.55, using intravenous sodium bicarbonate and hyperventilation (as needed), should be instituted for patients with dysrhythmias and/or QRS widening. A pH >7.60 or a pCO2 <20 mmHg is undesirable. Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide).

###  CNS

In patients with CNS depression, early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines or, if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in close consultation with a poison control center.
Disclosed herein is an amyloid ? accumulation and/or aggregation inhibitor. A technique for inhibiting amyloid ? accumulation and/or aggregation by concurrently introducing Nurr1 and Foxa2 genes and introducing the co-expression of the genes is also provided. When used, the composition can be applied to the prevention or treatment of a neurodegenerative disease caused by amyloid ? accumulation and/or aggregation, such as Alzheimer's disease.
1,034,437. Microcapsules. GEVAERT PHOTO-PRODUCTEN N.V. Feb. 20, 1963 [Feb. 20, 1962], No. 6860/63. Heading B8C. Solid particles and liquid droplets of a sparingly water-soluble or water-insoluble material are encapsulated in a mantle of a gelatine derivative which is insoluble in acid aqueous medium but soluble in medium of a higher pH by one of the following methods: (i) The material to be encapsulated is dispersed in an aqueous solution of a gelatine derivative of the said type and the dispersion is acidified to cause the gelatin derivative to coacervate and encapsulate the dispersion particles in a mantle which may be subsequently gelled, e.g. by cooling, and, if desired, hardened, e.g. by treatment with chrome alum. (ii) The material is dispersed in an aqueous solution of gelatin to which a reagent is subsequently added to react with the gelatin to form a derivative of the abovementioned type and which is caused to coacervate by acidification and encapsulate the dispersion, subsequent treatment being as in (i) above. (iii) The material is dispersed in an aqueous dispersion of the gelatin derivative which is already coacervated but not gelled whereby encapsulation of the particles occurs and subsequent treatment being as in (i) above. Suitable gelatine derivatives include the products of the reaction of gelatin with aliphatic and aromatic carboxylic acid anhydrides, compounds containing a reactive halogen atom, e.g. sulphonyl chlorides, sulphonyl fluorides, carbonyl chlorides, carbonyl bromides, chloroformates and other types of compound containing reactive halogen atoms, isocyanates and N-arylvinyl sulphonamides numerous specific examples of such compounds being given. Materials which may be encapsulated include those suitable for use in photography, e.g. N- hex - decyl - 1 - hydroxy - 2 - naphthamide (colour coupler) encapsulated in a gelatinesilver halide emulsion. Other specific examples relate to the encapsulation of paraffin oil, toluene and carbon tetrachloride.
Broad-spectrum antibiotics are frequently used to treat bacteria-induced infections, but the overuse of antibiotics may induce the gut microbiota dysbiosis and disrupt gastrointestinal tract function. Probiotics can be applied to restore disturbed gut microbiota and repair abnormal intestinal metabolism. In the present study, two strains of Enterococcus faecium (named DC-K7 and DC-K9) were isolated and characterized from the fecal samples of infant dogs. The genomic features of E. faecium DC-K7 and DC-K9 were analyzed, the carbohydrate-active enzyme (CAZyme)-encoding genes were predicted, and their abilities to produce short-chain fatty acids (SCFAs) were investigated. The bacteriocin-encoding genes in the genome sequences of E. faecium DC-K7 and DC-K9 were analyzed, and the gene cluster of Enterolysin-A, which encoded a 401-amino-acid peptide, was predicted. Moreover, the modulating effects of E. faecium DC-K7 and DC-K9 on the gut microbiota dysbiosis induced by antibiotics were analyzed. The current results demonstrated that oral administrations of E. faecium DC-K7 and DC-K9 could enhance the relative abundances of beneficial microbes and decrease the relative abundances of harmful microbes. Therefore, the isolated E. faecium DC-K7 and DC-K9 were proven to be able to alter the gut microbiota dysbiosis induced by antibiotic treatment.
Experimental and observational studies have shown that opioid analgesics may increase tumor growth, potentially reduce immunotherapy efficacy, and shorten survival. As a result of the lack of clinical data, the current rationale for continuing opioid analgesic treatment is based on animal models, which suggests that physical pain itself may potentially influence cancer growth and exert immunosuppressive effects. Total pain encompasses the various factors that patients may experience during their cancer journey: physical symptoms, social isolation/loneliness, psychological, spiritual/existential, and financial distress. These need to be screened and discussed with patients to help them cope with the treatment and disease. As each issue may affect survival, it is essential to identify them to understand how they might affect the patient's immune system, influence immunotherapy outcomes, and ultimately, survival. The question arises whether a single factor, such as the combination of opioids and immune checkpoint inhibitors, negatively affects treatment outcomes. While there is a risk of fostering opioid phobia, the complex interplay between total pain, quality of life, and the immune system must be considered. Thus, in studies that appropriately investigate the interactions between opioid analgesics and the immune system, it is essential to consider all the distress factors that patients may experience at each stage of their illness.
PURPOSE:To obtain a new eye makeup cosmetic soluble to silicone oil, excellent in resistance to water and oil, formulated with a silicone-based cinnamic acid derivative having ultraviolet light absorption characteristics for the UV-B wavelength region, and having effect of improving makeup sustainability. CONSTITUTION:This eye makeup cosmetic is such as to be formulated with a siloxane having at least one unit of formula I [R<1> is a 1-4C alkyl, phenyl or trimethylsiloxy; R<2> is a >=2C bifunctional hydrocarbon (including those bearing a heteroatom O); X is an alkoxyl; (n) is 0-3; (a) is 2 or 3], a silicone-based cinnamic acid derivative in which the other unit to be found in the siloxane is expressed by formula II (R<3> is a 1-4C alkyl, phenyl or trimethylsiloxy; (m) is 0-3). The silicone-based cinnamic acid derivative is e.g. a compound of formula III, IV. This cosmetic takes a form of eyeliner or eye shadow. It is preferable that a silicone-based base be used as the cosmetic base.
PROBLEM TO BE SOLVED: To automate air environment setting without setting an air environment by a troublesome remote controller by identifying an individual, measuring information relating to the health of the respective individuals and controlling an air conditioner installed corresponding to each individual for instance. SOLUTION: As initial values, the data (height, weight, body fat, blood pressure and pulse, etc.) of father, mother, brothers, sisters and grandfather are registered in a memory 22 beforehand. Then, the respective kinds of health data are measured and the total number of times of a group extracted in each measured value comparison is analyzed. For instance, when the father appears for five times, the brother appears for two times and the sister appears for two times, a control part 21 automatically judges that a measured person is the father by the appearing number of times.  Then, in the case of paring and transmitting the identification data (individual identification code) of the individual and the health data (individual data value) of the person, a paired data string is transmitted to the respective air conditioners 11-16 under the control of the control part 21 and an air conditioning environment corresponding to the preference of the father is automatically set for the father for instance.